Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BioGaia AB (publ) (BIOG-B.ST)
Stockholm, SE
BioGaia AB (publ), a Swedish enterprise founded in 1990 and headquartered in Stockholm, is dedicated to the worldwide development, marketing, and distribution of probiotic products renowned for their scientifically proven health advantages. The company operates through three primary divisions. Its Pediatrics segment offers various items such as drops, oral rehydration solutions, and gut health tablets, in addition to supplying cultures for integration into infant formula. The Adult Health segment provides gut health tablets and oral health lozenges, alongside furnishing cultures to licensees for use in dairy products. A third segment, "Other," specializes in packaging solutions. BioGaia's extensive product portfolio targets a range of health issues, including infantile colic and digestive health in children, antibiotic-associated and acute diarrhea, gingivitis, periodontal disease, general well-being, Helicobacter pylori bacterial infections (linked to gastric ulcers), and concerns related to low bone density. All of its offerings are sold exclusively under the BioGaia brand.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.31% | +9.57% | +9.75% | +34.25% | +27.49% | +25.43% | +28.86% | +29.37% | +64.01% | +219.66% | +3,558.33% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+8.1% ★ Q1'26: +1.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-5.2% Q1'26: -1.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+20.2% Q1'26: +18.5% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+27.9% ★ Q1'26: +27.8% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+66.2% ★ Q1'26: +61.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.1% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.00× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
483.24M
est: 501.45M (-3.6%)
|
534.70M
est: 536.95M (-0.4%)
|
615.00M
est: 601.67M (+2.2%)
|
741.87M
est: 725.00M (+2.3%)
|
768.35M
est: 769.00M (-0.1%)
|
747.08M
est: 743.50M (+0.5%)
|
785.11M
est: 768.87M (+2.1%)
|
1.10B
est: 1.12B (-1.4%)
|
1.30B
est: 1.37B (-5.3%)
|
1.42B
est: 1.39B (+2.2%)
|
1.54B
est: 1.49B (+3.5%)
|
1.66B
1.66B – 1.66B
+11.7% YoY
|
1.84B
1.84B – 1.84B
+11.1% YoY
|
2.04B
2.04B – 2.04B
+10.8% YoY
|
| EBITDA |
177.64M
est: 188.40M (-5.7%)
|
202.09M
est: 201.74M (+0.2%)
|
240.42M
est: 226.06M (+6.4%)
|
282.96M
est: 272.40M (+3.9%)
|
258.52M
est: 288.93M (-10.5%)
|
248.84M
est: 279.35M (-10.9%)
|
276.86M
est: 288.88M (-4.2%)
|
476.89M
est: 420.81M (+13.3%)
|
494.92M
est: 504.18M (-1.8%)
|
539.44M
est: 512.75M (+5.2%)
|
454.33M
est: 546.99M (-16.9%)
|
611.17M
611.17M – 611.17M
+11.7% YoY
|
679.04M
679.04M – 679.04M
+11.1% YoY
|
752.68M
752.68M – 752.68M
+10.8% YoY
|
| EBIT |
171.09M
est: 173.18M (-1.2%)
|
195.01M
est: 185.44M (+5.2%)
|
233.73M
est: 207.79M (+12.5%)
|
278.00M
est: 250.38M (+11.0%)
|
242.93M
est: 265.57M (-8.5%)
|
228.31M
est: 256.77M (-11.1%)
|
253.84M
est: 265.53M (-4.4%)
|
453.00M
est: 386.79M (+17.1%)
|
469.64M
est: 465.73M (+0.8%)
|
462.74M
est: 473.65M (-2.3%)
|
429.67M
est: 505.27M (-15.0%)
|
564.56M
564.56M – 564.56M
+11.7% YoY
|
627.25M
627.25M – 627.25M
+11.1% YoY
|
695.27M
695.27M – 695.27M
+10.8% YoY
|
| Net Income |
121.41M
est: 134.01M (-9.4%)
|
227.57M
est: 166.57M (+36.6%)
|
180.56M
est: 201.81M (-10.5%)
|
214.89M
est: 246.28M (-12.7%)
|
187.35M
est: 214.27M (-12.6%)
|
179.73M
est: 204.77M (-12.2%)
|
196.27M
est: 201.74M (-2.7%)
|
373.77M
est: 296.14M (+26.2%)
|
365.35M
est: 402.43M (-9.2%)
|
351.39M
est: 373.29M (-5.9%)
|
332.76M
est: 313.94M (+6.0%)
|
405.32M
405.32M – 405.32M
+29.1% YoY
|
480.86M
480.86M – 480.86M
+18.6% YoY
|
549.65M
549.65M – 549.65M
+14.3% YoY
|
| SGA |
114.81M
est: 153.19M (-25.1%)
|
129.00M
est: 164.03M (-21.4%)
|
149.18M
est: 183.80M (-18.8%)
|
180.76M
est: 221.48M (-18.4%)
|
208.94M
est: 234.92M (-11.1%)
|
197.76M
est: 227.13M (-12.9%)
|
234.98M
est: 234.88M (+0.0%)
|
360.62M
est: 342.15M (+5.4%)
|
402.51M
est: 445.70M (-9.7%)
|
464.28M
est: 453.28M (+2.4%)
|
560.89M
est: 483.55M (+16.0%)
|
540.29M
540.29M – 540.29M
+11.7% YoY
|
600.29M
600.29M – 600.29M
+11.1% YoY
|
665.38M
665.38M – 665.38M
+10.8% YoY
|
| EPS |
1.40
est: 1.33 (+5.6%)
|
2.63
est: 1.65 (+59.6%)
|
2.08
est: 2.00 (+4.2%)
|
2.48
est: 2.44 (+1.8%)
|
2.16
est: 2.12 (+1.9%)
|
1.78
est: 2.03 (-12.1%)
|
1.94
est: 2.00 (-2.8%)
|
3.70
est: 2.93 (+26.3%)
|
3.62
est: 3.98 (-9.0%)
|
3.47
est: 3.69 (-6.0%)
|
3.29
est: 3.10 (+6.0%)
|
4.01
4.01 – 4.01
+29.1% YoY
|
4.75
4.75 – 4.75
+18.6% YoY
|
5.43
5.43 – 5.43
+14.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.07% | 2.38M | 0.30% |
| 2 | iShares MSCI Europe Small-Cap ETF IEUS | 0.07% | 117.2K | 0.41% |
| 3 | iShares International Small-Cap Equity Factor ETF ISCF | 0.06% | 402.0K | 0.24% |
| 4 | Avantis International Small Cap Equity ETF AVDS | 0.05% | 154.6K | 0.30% |
| 5 | UBS MSCI World Small Cap Socially Responsible UCITS ETF USD dis WSCR.L | 0.04% | 333.4K | 0.23% |
| 6 | UBS MSCI World Small Cap Socially Responsible UCITS ETF USD acc WSCSRI.SW | 0.04% | 333.6K | 0.23% |
| 7 | Dimensional - International Small Cap ETF DFIS | 0.03% | 1.83M | 0.39% |
| 8 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.03% | 102.9K | 0.23% |
| 9 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.03% | 102.9K | 0.23% |
| 10 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.03% | 66.1K | 0.83% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Theresa Agnew | Chief Executive Officer & President | 9M | female |
| Alexander Kotsinas | Executive Vice President & Chief Financial Officer | 4M | male |
| Caroline Mofors | Executive Vice President & Chief Legal Officer | — | female |
| Darryl Mallette | Managing Director Canada | — | male |
| Gianfranco Grompone | Chief Scentific Officer | — | male |
| Jennifer Cherry | Managing Director USA | — | — |
| Jonathan Gromark | Sustainability Manager | — | — |
| Linda Hagglund | Chief Marketing Officer | — | female |
| Ludvig Milesson | Chief Operating Officer | — | — |
| Minna Tähtinen | Managing Director Finland | — | — |
| Angelika Kjelldorff | Chief Human Resources Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BIOG-B.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
